Urothelial Cancer Treatment Market

Key Highlights of the report

How are the major segments performing in the Urothelial Cancer Treatment market?

• In 2022, the chemotherapy segment accounted for the largest market share since the medications can be used alone or in combination, depending on their intended use.
• In 2022, the flat carcinoma segment was anticipated to hold a prominent share in the global urothelial cancer treatment market numerous innovative treatments receiving approval during the projection period.
• In 2022, the hospital segment dominated the global market share during the forecast period owing to an increased flow of patients presenting with various ailments.
• In 2022, the retail pharmacies are expected to retain the largest market share during the forecast period owing to rising number of pharmacies combined with rising availability of medications.

What is the Market Size of Urothelial Cancer Treatment regarding value?

The global urothelial cancer treatment market is anticipated to grow at a substantial CAGR of 22.3% in the upcoming years. The global urothelial cancer treatment industry was estimated to be worth USD 845.6 million in 2022 and was expected to be worth USD 3461.8 million by 2028.

Which region dominated the Urothelial Cancer Treatment market?

In 2022, the Asia Pacific region was anticipated to hold a prominent share in the global urothelial cancer treatment market. China has a significant possibility for commercial expansion. The presence of a large target population and high unmet clinical needs are projected to boost the market in this area. Numerous local businesses are presently investigating drugs in Phase II trials as second/third-line treatments and are well-positioned to enter the China market in the future.

How is US Market Performing in the Urothelial Cancer Treatment market?

In 2022, the United States region was anticipated to hold a prominent share in the global urothelial cancer treatment market. The presence of a large target population, increased use of innovative therapies, and several product launches are projected to drive market expansion throughout the projection period. For example, according to GLOBOCAN data updated in 2020, around 90,000 new cases of bladder cancer were recorded in the United States in 2020, with this figure anticipated to rise to 137,000 by 2040.

How is the economy impacting the global Urothelial Cancer Treatment growth?

Analysts have forecast a US recession for nearly a year. No government agency has announced this yet. Financial circumstances slowdown in recessions. Recessions can follow two-quarters of negative GDP growth. US GDP fell 1.6% in the first month and 0.6% in the second. The Russia-Ukraine conflict has raised power prices worldwide. According to some reports, the European Union, the G-7, and their latest partners will put a fuel cap on Russia’s exports starting February 5th. This is their latest punishment for illegally invading Ukraine.

What is the competitive environment of the Urothelial Cancer Treatment market?

Roche, Merck, Bristol-Myers Squibb, AstraZeneca, and Pfizer are major participants in this sector. Collaborations for development, expanded product portfolios, and regional expansion in emerging markets are significant strategic initiatives for these organizations as they seek to improve their market share. The market is expected to become highly congested, with multiple product launches scheduled during the projected period. Merck and AstraZeneca will likely lead the market in 2023, thanks to the approval of (Imfinzi + tremelimumab) and (Keytruda + chemotherapy) regimens in early lines of treatment for both chemo-ineligible and chemo-eligible patients. Immune checkpoint blockade therapy is projected to replace the current standard of care in bladder cancer. For instance, Merck has announced a label update for its anti-PD-1 medication KEYTRUDA in the United States’ first-line advanced urothelial carcinoma (bladder cancer). This indication was converted from an accelerated to a full (normal) approval by the United States Food and Drug Administration (USFDA).

Executive Summary

What are the key trends in the Urothelial Cancer Treatment market?

• Urothelial cancer dare drugs are on the rise alongside the ageing population, disorganised lifestyles, and increased public awareness, all of which bode well for market expansion.
• Cancer that begins in the urothelium is called urothelial carcinoma or transitional cell carcinoma. There are around 2.5 million people living with the disease, and 420,000 new cases are identified annually, making it the tenth most frequent cancer worldwide.

How are Analgesics Impacting the Growth of the Global Urothelial Cancer Treatment Market?

In addition, the overuse of analgesics is thought to fuel the market expansion of urothelial carcinoma treatment. Analgesics, or “painkillers,” are medications used to treat various ailments, including headaches, injuries, and arthritis. Pain relievers are safe; if taken too frequently, for too long, or in very large dosages, they may cause undesirable side effects and complications. Furthermore, urinary tract cancer and atherosclerotic disease are two serious side effects of long-term heavy painkiller use. For example, painkiller use is the most common cause of bladder cancer in women under 50.

Which are the key investments by the Urothelial Cancer Treatment market players?

As a result of the presence of a large number of leading players in the market, the worldwide urothelial cancer treatment sector is anticipated to be extremely competitive. In addition, key players in the industry are incorporating digital technology into the industrial and operational components of the business to achieve a competitive advantage. Producers are contemplating expanding their production capacities to satisfy the consumer market’s requirements. For instance, Pfizer made a USD 25 million equity investment in Zentalis Pharmaceuticals, Inc. This investment is likely to assist Pfizer in leveraging its global development capabilities.

Some major players in the urothelial cancer treatment market are Johnson & Johnson Private Limited, Abbott, AbbVie Inc, Bausch Health Companies Inc, Sun Pharmaceutical Industries Ltd., urobindo Pharma, Lupin, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Pfizer Inc, Mylan N.V., Bristol-Myers Squibb Company, GSK plc., Bayer AG, Dendreon Pharmaceuticals LLC, Eisai Co., Ltd, Genentech, Inc, F. Hoffmann-La Roche Ltd., UroGen Pharma, Inc., Koninklijke Philips N.V., Olympus Corporation, Pacific Edge, AroCell AB, and Agilent Technologies Inc.

What are the Major Driving Factors for the Urothelial Cancer Treatment Market?

The availability of innovative medications, the presence of a solid pipeline, the rise in the prevalence of urothelial carcinoma due to the growing senior population, a disorganized lifestyle, and rising public awareness are all factors driving market expansion. Urothelial or transitional cell carcinoma is a malignant tumor that develops from the urothelium. With around 2.5 million patients and 420,000 newly diagnosed cases each year, the disease is the tenth most frequent cancer in the world. Bladder transitional cell carcinoma (TCC) accounted for around 90% of all occurrences of urine cancer. Urothelial cancer is classified clinically into three types: non-muscle invasive bladder cancer (NMIBC), muscle-invasive disease (MIBC), and metastatic disease (late-stage). At the time of diagnosis, roughly 70% of cases are non-muscle invasive illnesses, 20% are muscle-invasive, and 10% are advanced. Developed regions such as North America and Europe account for 59% of bladder cancer cases. Urothelial cancer economic and human toll reflects an unequal health burden. Because of its high relapse incidence and invasive lifelong monitoring, including cystoscopy follow-ups, the illness has the highest lifetime cost of care per patient of all malignancies in the United States.

What are the Major Risks for the Urothelial Cancer Treatment Market?

The high R&D costs associated with the manufacture of urothelial cancer therapies and growing generic medication penetration are projected to stifle market growth. Yet, the adverse effects of medications on healthy cells in the body limit market expansion.

Which is the key Treatment in the Urothelial Cancer Treatment market?

An increase in the use of chemotherapy, the prevalence of bladder cancer, and product launches by key market participants are driving the segment. Chemotherapy is the most commonly utilized therapeutic method for stopping or slowing the growth of urothelial carcinoma cells. It acts throughout the body to eliminate and harm cancer cells that have spread from the initial tumor to other body parts. The first-line treatments for advanced or metastatic urothelial carcinoma have been gemcitabine plus cisplatin (GC) and methotrexate, vinblastine, adriamycin, and cisplatin (MVAC), according to a study published in January 2020 titled “Efficacy and Safety of Chemotherapy Regimens in Advanced or Metastatic Bladder and Urothelial Carcinomas: An Updated Network Meta-Analysis” (AMUC). Furthermore, according to the findings of the ‘Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a Phase III, open-label, randomized controlled trial’ published in March 2020, gemcitabine-platinum combination chemotherapy significantly improved outcomes in patients with upper tract urothelial carcinoma. Such research is predicted to boost market expansion in this sector.

How is the Urothelial Cancer Treatment market performing in regions?

The North American market is anticipated to witness the fastest growth in the global urothelial cancer treatment market during the forecast period. The introduction of COVID-19 substantially impacted the urothelial cancer medications market. As a result, organizations such as the American College of Surgeons (ACS) have issued suggestions to help assist patients through treatment delays. The presence of a large target population, increased use of innovative therapies, and several product launches are projected to drive market expansion throughout the projection period. For example, according to GLOBOCAN data updated in 2020, around 90,000 new cases of bladder cancer were recorded in North America in 2020, with this figure anticipated to rise to 137,000 by 2040. Furthermore, various strategies used by leading industry competitors are aiding market expansion. Pfizer, for example, got approval from the US Food and Drug Administration for BAVENCIO in June 2020. It has been approved as a first-line maintenance treatment for advanced/metastatic urothelial carcinoma patients.

What is the regulatory landscape for the Urothelial Cancer Treatment market?

Most hospitals employ the American Joint Committee on Cancer (AJCC) 13 tumour, node, metastasis (TNM) staging system (see “Staging” in the complete version of these guidelines at NCCN.org). The National Comprehensive Cancer Network (NCCN) Bladder Cancer Guidelines classify bladder urothelial carcinoma as either non-muscle-invasive (Ta, T1, and Tis) or muscle-invasive (T2 disease). Careful attention to histology, grade, and depth of invasion is paid when managing bladder cancer based on the results of a biopsy and TURBT. These variables calculate the likelihood of recurrence and progression to a more advanced state.

What are the major players planning for the future of the Urothelial Cancer Treatment market?

The global urothelial cancer treatment industry comprises players who use various techniques to stay on top of the competitive field. Mergers and acquisitions are among these methods, as are ongoing advancements in manufacturing and production procedures. For instance, in March 2022, Pfizer signed a two-year research collaboration deal with NetVation DL Medicine. This agreement is expected to help develop Pfizer’s research initiatives. In June 2022, Roche launched the human papillomavirus (HPV) self-sampling method, allowing people to screen for HPV in the presence of a healthcare provider. This is intended to broaden the company’s cancer screening solution portfolio.

Segmentation of Global Urothelial Cancer Treatment Market-

Global Urothelial Cancer Treatment Market – By Types

• Papillary
• Flat Carcinoma

Global Urothelial Cancer Treatment Market – By Treatment

• Chemotherapy
• Radiotherapy
• Immunotherapy
• Diagnostic Test
• Urine Cytology
• Biopsy
• Computed tomography scanning
• Ultrasound Imaging
• Cystoscopy
• Others

Global Urothelial Cancer Treatment Market – By End-User

• Hospitals
• Homecare
• Specialty Centres
• Others

Global Urothelial Cancer Treatment Market – By Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Urothelial Cancer Treatment Market – By Region

• North America
  • Canada
• Europe
  • Germany
  • France
  • K.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • South-east Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Approach Adopted
1.3.4.1. Top-Down Approach
1.3.4.2. Bottom-Up Approach
1.3.5. Assumptions
1.4. Market Introduction
1.5. Market Research Scope

2. Executive Summary
2.1. Market Snapshot: Global Urothelial Cancer Treatment Market
2.2. Global Urothelial Cancer Treatment Market, By Type
2.3. Global Urothelial Cancer Treatment Market, By Treatment
2.4. Global Urothelial Cancer Treatment Market, By End-Users
2.5. Global Urothelial Cancer Treatment Market, By Distribution Channel
2.6. Global Urothelial Cancer Treatment Market, By Region

3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Urothelial Cancer Treatment Market Value, 2017-2030, (US$ Mn))
3.1.2. Y-o-Y Growth Trend Analysis
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.2. Market Restraints
3.2.3. Market Opportunities
3.2.4. Major Industry Challenges
3.3. Growth and Development Patterns
3.4. Investment Feasibility Analysis
3.5. Market Opportunity Analysis
3.5.1. Type
3.5.2. Treatment
3.5.3. End-Users
3.5.4. Distribution Channel
3.5.5. Geography

4. Premium Insights
4.1. STAR (Situation, Task, Action, Results) Analysis
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers/Consumers
4.2.3. Bargaining Power of Suppliers
4.2.4. Threat of Substitute Types
4.2.5. Intensity of Competitive Rivalry
4.3. Key Market Trends
4.3.1. Demand Side Trends
4.3.2. Supply Side Trends
4.4. Value Chain Analysis
4.5. Type Analysis
4.6. Analysis and Recommendations
4.7. Marketing Strategy Analysis
4.7.1. Direct Marketing
4.7.2. Indirect Marketing
4.7.3. Marketing Channel Development Trend

5. Market Positioning of Key Players, 2022
5.1. Company market share of key players, 2022
5.2. Competitive Benchmarking
5.3. Market Positioning of Key Vendors
5.4. Geographical Presence Analysis
5.5. Major Strategies Adopted by Key Players
5.5.1. Key Strategies Analysis
5.5.2. Mergers and Acquisitions
5.5.3. Partnerships
5.5.4. Product Launch
5.5.5. Geographical Expansion
5.5.6. Others

6. Economic Impact Analysis
6.1. Recession Impact
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Latin America
6.1.5. Middle East and Africa
6.2. Ukraine-Russia War Impact
6.2.1. North America
6.2.2. Europe
6.2.3. Asia Pacific
6.2.4. Latin America
6.2.5. Middle East and Africa
6.3. COVID-19 Impact Analysis
6.3.1. North America
6.3.2. Europe
6.3.3. Asia Pacific
6.3.4. Latin America
6.3.5. Middle East and Africa

7. Global Urothelial Cancer Treatment Market
7.1. Global Urothelial Cancer Treatment Market, by Type, 2017-2030 (US$ Mn))
7.1.1. Overview
7.1.2. Global Urothelial Cancer Treatment Market, By Type, 2022 vs 2030 (in%)
7.1.3. Global Urothelial Cancer Treatment Market, By Papillary, 2017-2030 (US$ Mn))
7.1.4. Global Urothelial Cancer Treatment Market, By Flat Carcinoma, 2017-2030 (US$ Mn))
7.2. Global Urothelial Cancer Treatment Market, by Treatment, 2017-2030 (US$ Mn))
7.2.1. Overview
7.2.2. Global Urothelial Cancer Treatment Market, By Treatment, 2022 vs 2030 (in%)
7.2.3. Global Urothelial Cancer Treatment Market, By Chemotherapy, 2017-2030 (US$ Mn))
7.2.4. Global Urothelial Cancer Treatment Market, By Radiotherapy, 2017-2030 (US$ Mn))
7.2.5. Global Urothelial Cancer Treatment Market, By Immunotherapy, 2017-2030 (US$ Mn))
7.2.6. Global Urothelial Cancer Treatment Market, By Diagnostic Test, 2017-2030 (US$ Mn))
7.2.7. Global Urothelial Cancer Treatment Market, By Urine Cytology, 2017-2030 (US$ Mn))
7.2.8. Global Urothelial Cancer Treatment Market, By Biopsy, 2017-2030 (US$ Mn))
7.2.9. Global Urothelial Cancer Treatment Market, By Computed tomography scanning, 2017-2030 (US$ Mn))
7.2.10. Global Urothelial Cancer Treatment Market, By Ultrasound Imaging, 2017-2030 (US$ Mn))
7.2.11. Global Urothelial Cancer Treatment Market, By Cystoscopy, 2017-2030 (US$ Mn))
7.2.12. Global Urothelial Cancer Treatment Market, By Others, 2017-2030 (US$ Mn))
7.3. Global Urothelial Cancer Treatment Market, by End-Users, 2017-2030 (US$ Mn))
7.3.1. Overview
7.3.2. Global Urothelial Cancer Treatment Market, By End-Users, 2022 vs 2030 (in%)
7.3.3. Global Urothelial Cancer Treatment Market, By Hospitals, 2017-2030 (US$ Mn))
7.3.4. Global Urothelial Cancer Treatment Market, By Homecare, 2017-2030 (US$ Mn))
7.3.5. Global Urothelial Cancer Treatment Market, By Speciality Centres, 2017-2030 (US$ Mn))
7.3.6. Global Urothelial Cancer Treatment Market, By Others, 2017-2030 (US$ Mn))

8. North America Urothelial Cancer Treatment Market Analysis
8.1. North America Urothelial Cancer Treatment Market, by Type, 2017-2030(US$ Mn))
8.1.1. Overview
8.1.2. SRC Analysis
8.2. North America Urothelial Cancer Treatment Market, by Treatment, 2017-2030(US$ Mn))
8.2.1. Overview
8.2.2. SRC Analysis
8.3. North America Urothelial Cancer Treatment Market, by End-Users, 2017-2030(US$ Mn))
8.3.1. Overview
8.3.2. SRC Analysis
8.4. North America Urothelial Cancer Treatment Market, by Distribution Channel, 2017-2030(US$ Mn))
8.4.1. Overview
8.4.2. SRC Analysis
8.5. North America Urothelial Cancer Treatment Market, by Country, 2017-2030 (US$ Mn))
8.5.1. U.S.
8.5.1.1. U.S. Urothelial Cancer Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
8.5.1.2. U.S. Urothelial Cancer Treatment, By Type, 2017-2030 (US$ Mn))
8.5.1.3. U.S. Urothelial Cancer Treatment, By Treatment, 2017-2030 (US$ Mn))
8.5.1.4. U.S. Urothelial Cancer Treatment, By End-Users, 2017-2030 (US$ Mn))
8.5.1.5. U.S. Urothelial Cancer Treatment, By Distribution Channel, 2017-2030 (US$ Mn))
8.5.2. Canada
8.5.2.1. Canada Urothelial Cancer Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
8.5.2.2. Canada Urothelial Cancer Treatment, By Type, 2017-2030 (US$ Mn))
8.5.2.3. Canada Urothelial Cancer Treatment, By Treatment, 2017-2030 (US$ Mn))
8.5.2.4. Canada Urothelial Cancer Treatment, By End-Users, 2017-2030 (US$ Mn))
8.5.2.5. Canada Urothelial Cancer Treatment, By Distribution Channel, 2017-2030 (US$ Mn))

9. Europe Urothelial Cancer Treatment Market Analysis
9.1. Europe Urothelial Cancer Treatment Market, by Type, 2017-2030(US$ Mn))
9.1.1. Overview
9.1.2. SRC Analysis
9.2. Europe Urothelial Cancer Treatment Market, by Treatment, 2017-2030(US$ Mn))
9.2.1. Overview
9.2.2. SRC Analysis
9.3. Europe Urothelial Cancer Treatment Market, by End-Users, 2017-2030(US$ Mn))
9.3.1. Overview
9.3.2. SRC Analysis
9.4. Europe Urothelial Cancer Treatment Market, by Distribution Channel, 2017-2030(US$ Mn))
9.4.1. Overview
9.4.2. SRC Analysis
9.5. Europe Urothelial Cancer Treatment Market, by Country, 2017-2030 (US$ Mn))
9.5.1. Germany
9.5.1.1. Germany Urothelial Cancer Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
9.5.1.2. Germany Urothelial Cancer Treatment, By Type, 2017-2030 (US$ Mn))
9.5.1.3. Germany Urothelial Cancer Treatment, By Treatment, 2017-2030 (US$ Mn))
9.5.1.4. Germany Urothelial Cancer Treatment, By End-Users, 2017-2030 (US$ Mn))
9.5.1.5. Germany Urothelial Cancer Treatment, By Distribution Channel, 2017-2030 (US$ Mn))
9.5.2. France
9.5.2.1. France Urothelial Cancer Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
9.5.2.2. France Urothelial Cancer Treatment, By Type, 2017-2030 (US$ Mn))
9.5.2.3. France Urothelial Cancer Treatment, By Treatment, 2017-2030 (US$ Mn))
9.5.2.4. France Urothelial Cancer Treatment, By End-Users, 2017-2030 (US$ Mn))
9.5.2.5. France Urothelial Cancer Treatment, By Distribution Channel, 2017-2030 (US$ Mn))
9.5.3. UK
9.5.3.1. UK Urothelial Cancer Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
9.5.3.2. UK Urothelial Cancer Treatment, By Type, 2017-2030 (US$ Mn))
9.5.3.3. UK Urothelial Cancer Treatment, By Treatment, 2017-2030 (US$ Mn))
9.5.3.4. UK Urothelial Cancer Treatment, By End-Users, 2017-2030 (US$ Mn))
9.5.3.5. UK Urothelial Cancer Treatment, By Distribution Channel, 2017-2030 (US$ Mn))
9.5.4. Italy
9.5.4.1. Italy Urothelial Cancer Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
9.5.4.2. Italy Urothelial Cancer Treatment, By Type, 2017-2030 (US$ Mn))
9.5.4.3. Italy Urothelial Cancer Treatment, By Treatment, 2017-2030 (US$ Mn))
9.5.4.4. Italy Urothelial Cancer Treatment, By End-Users, 2017-2030 (US$ Mn))
9.5.4.5. Italy Urothelial Cancer Treatment, By Distribution Channel, 2017-2030 (US$ Mn))
9.5.5. Spain
9.5.5.1. Spain Urothelial Cancer Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
9.5.5.2. Spain Urothelial Cancer Treatment, By Type, 2017-2030 (US$ Mn))
9.5.5.3. Spain Urothelial Cancer Treatment, By Treatment, 2017-2030 (US$ Mn))
9.5.5.4. Spain Urothelial Cancer Treatment, By End-Users, 2017-2030 (US$ Mn))
9.5.5.5. Spain Urothelial Cancer Treatment, By Distribution Channel, 2017-2030 (US$ Mn))
9.5.6. Rest of Europe
9.5.6.1. Rest of Europe Urothelial Cancer Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
9.5.6.2. Rest of Europe Urothelial Cancer Treatment, By Type, 2017-2030 (US$ Mn))
9.5.6.3. Rest of Europe Urothelial Cancer Treatment, By Treatment, 2017-2030 (US$ Mn))
9.5.6.4. Rest of Europe Urothelial Cancer Treatment, By End-Users, 2017-2030 (US$ Mn))
9.5.6.5. Rest of Europe Urothelial Cancer Treatment, By Distribution Channel, 2017-2030 (US$ Mn))

10. Asia Pacific Urothelial Cancer Treatment Market Analysis
10.1. Asia Pacific Urothelial Cancer Treatment Market, by Type, 2017-2030(US$ Mn))
10.1.1. Overview
10.1.2. SRC Analysis
10.2. Asia Pacific Urothelial Cancer Treatment Market, by Treatment, 2017-2030(US$ Mn))
10.2.1. Overview
10.2.2. SRC Analysis
10.3. Asia Pacific Urothelial Cancer Treatment Market, by End-Users, 2017-2030(US$ Mn))
10.3.1. Overview
10.3.2. SRC Analysis
10.4. Asia Pacific Urothelial Cancer Treatment Market, by Distribution Channel, 2017-2030(US$ Mn))
10.4.1. Overview
10.4.2. SRC Analysis
10.5. Asia Pacific Urothelial Cancer Treatment Market, by Country, 2017-2030 (US$ Mn))
10.5.1. China
10.5.1.1. China Urothelial Cancer Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
10.5.1.2. China Urothelial Cancer Treatment, By Type, 2017-2030 (US$ Mn))
10.5.1.3. China Urothelial Cancer Treatment, By Treatment, 2017-2030 (US$ Mn))
10.5.1.4. China Urothelial Cancer Treatment, By End-Users, 2017-2030 (US$ Mn))
10.5.1.5. China Urothelial Cancer Treatment, By Distribution Channel, 2017-2030 (US$ Mn))
10.5.2. Japan
10.5.2.1. Japan Urothelial Cancer Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
10.5.2.2. Japan Urothelial Cancer Treatment, By Type, 2017-2030 (US$ Mn))
10.5.2.3. Japan Urothelial Cancer Treatment, By Treatment, 2017-2030 (US$ Mn))
10.5.2.4. Japan Urothelial Cancer Treatment, By End-Users, 2017-2030 (US$ Mn))
10.5.2.5. Japan Urothelial Cancer Treatment, By Distribution Channel, 2017-2030 (US$ Mn))
10.5.3. India
10.5.3.1. India Urothelial Cancer Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
10.5.3.2. India Urothelial Cancer Treatment, By Type, 2017-2030 (US$ Mn))
10.5.3.3. India Urothelial Cancer Treatment, By Treatment, 2017-2030 (US$ Mn))
10.5.3.4. India Urothelial Cancer Treatment, By End-Users, 2017-2030 (US$ Mn))
10.5.3.5. India Urothelial Cancer Treatment, By Distribution Channel, 2017-2030 (US$ Mn))
10.5.4. South Korea
10.5.4.1. South Korea Urothelial Cancer Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
10.5.4.2. South Korea Urothelial Cancer Treatment, By Type, 2017-2030 (US$ Mn))
10.5.4.3. South Korea Urothelial Cancer Treatment, By Treatment, 2017-2030 (US$ Mn))
10.5.4.4. South Korea Urothelial Cancer Treatment, By End-Users, 2017-2030 (US$ Mn))
10.5.4.5. South Korea Urothelial Cancer Treatment, By Distribution Channel, 2017-2030 (US$ Mn))
10.5.5. South-East Asia
10.5.5.1. South-East Asia Urothelial Cancer Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
10.5.5.2. South-East Asia Urothelial Cancer Treatment, By Type, 2017-2030 (US$ Mn))
10.5.5.3. South-East Asia Urothelial Cancer Treatment, By Treatment, 2017-2030 (US$ Mn))
10.5.5.4. South-East Asia Urothelial Cancer Treatment, By End-Users, 2017-2030 (US$ Mn))
10.5.5.5. South-East Asia Urothelial Cancer Treatment, By Distribution Channel, 2017-2030 (US$ Mn))
10.5.6. Rest of Asia Pacific
10.5.6.1. Rest of Asia Pacific Urothelial Cancer Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
10.5.6.2. Rest of Asia Pacific Urothelial Cancer Treatment, By Type, 2017-2030 (US$ Mn))
10.5.6.3. Rest of Asia Pacific Urothelial Cancer Treatment, By Treatment, 2017-2030 (US$ Mn))
10.5.6.4. Rest of Asia Pacific Urothelial Cancer Treatment, By End-Users, 2017-2030 (US$ Mn))
10.5.6.5. Rest of Asia Pacific Urothelial Cancer Treatment, By Distribution Channel, 2017-2030 (US$ Mn))

11. Latin America Urothelial Cancer Treatment Market Analysis
11.1. Latin America Urothelial Cancer Treatment Market, by Type, 2017-2030(US$ Mn))
11.1.1. Overview
11.1.2. SRC Analysis
11.2. Latin America Urothelial Cancer Treatment Market, by Treatment, 2017-2030(US$ Mn))
11.2.1. Overview
11.2.2. SRC Analysis
11.3. Latin America Urothelial Cancer Treatment Market, by End-Users, 2017-2030(US$ Mn))
11.3.1. Overview
11.3.2. SRC Analysis
11.4. Latin America Urothelial Cancer Treatment Market, by Distribution Channel, 2017-2030(US$ Mn))
11.4.1. Overview
11.4.2. SRC Analysis
11.5. Latin America Urothelial Cancer Treatment Market, by Country, 2017-2030 (US$ Mn))
11.5.1. Brazil
11.5.1.1. Brazil Urothelial Cancer Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
11.5.1.2. Brazil Urothelial Cancer Treatment, By Type, 2017-2030 (US$ Mn))
11.5.1.3. Brazil Urothelial Cancer Treatment, By Treatment, 2017-2030 (US$ Mn))
11.5.1.4. Brazil Urothelial Cancer Treatment, By End-Users, 2017-2030 (US$ Mn))
11.5.1.5. Brazil Urothelial Cancer Treatment, By Distribution Channel, 2017-2030 (US$ Mn))
11.5.2. Mexico
11.5.2.1. Mexico Urothelial Cancer Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
11.5.2.2. Mexico Urothelial Cancer Treatment, By Type, 2017-2030 (US$ Mn))
11.5.2.3. Mexico Urothelial Cancer Treatment, By Treatment, 2017-2030 (US$ Mn))
11.5.2.4. Mexico Urothelial Cancer Treatment, By End-Users, 2017-2030 (US$ Mn))
11.5.2.5. Mexico Urothelial Cancer Treatment, By Distribution Channel, 2017-2030 (US$ Mn))
11.5.3. Rest of Latin America
11.5.3.1. Rest of Latin America Urothelial Cancer Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
11.5.3.2. Rest of Latin America Urothelial Cancer Treatment, By Type, 2017-2030 (US$ Mn))
11.5.3.3. Rest of Latin America Urothelial Cancer Treatment, By Treatment, 2017-2030 (US$ Mn))
11.5.3.4. Rest of Latin America Urothelial Cancer Treatment, By End-Users, 2017-2030 (US$ Mn))
11.5.3.5. Rest of Latin America Urothelial Cancer Treatment, By Distribution Channel, 2017-2030 (US$ Mn))

12. Middle East and Africa Urothelial Cancer Treatment Market Analysis
12.1. Middle East and Africa Urothelial Cancer Treatment Market, by Type, 2017-2030(US$ Mn))
12.1.1. Overview
12.1.2. SRC Analysis
12.2. Middle East and Africa Urothelial Cancer Treatment Market, by Treatment, 2017-2030(US$ Mn))
12.2.1. Overview
12.2.2. SRC Analysis
12.3. Middle East and Africa Urothelial Cancer Treatment Market, by End-Users, 2017-2030(US$ Mn))
12.3.1. Overview
12.3.2. SRC Analysis
12.4. Middle East and Africa Urothelial Cancer Treatment Market, by Distribution Channel, 2017-2030(US$ Mn))
12.4.1. Overview
12.4.2. SRC Analysis
12.5. Middle East and Africa Urothelial Cancer Treatment Market, by Country, 2017-2030 (US$ Mn))
12.5.1. GCC Countries
12.5.1.1. GCC Countries Urothelial Cancer Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
12.5.1.2. GCC Countries Urothelial Cancer Treatment, By Type, 2017-2030 (US$ Mn))
12.5.1.3. GCC Countries Urothelial Cancer Treatment, By Treatment, 2017-2030 (US$ Mn))
12.5.1.4. GCC Countries Urothelial Cancer Treatment, By End-Users, 2017-2030 (US$ Mn))
12.5.1.5. GCC Countries Urothelial Cancer Treatment, By Distribution Channel, 2017-2030 (US$ Mn))
12.5.2. South Africa
12.5.2.1. South Africa Urothelial Cancer Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
12.5.2.2. South Africa Urothelial Cancer Treatment, By Type, 2017-2030 (US$ Mn))
12.5.2.3. South Africa Urothelial Cancer Treatment, By Treatment, 2017-2030 (US$ Mn))
12.5.2.4. South Africa Urothelial Cancer Treatment, By End-Users, 2017-2030 (US$ Mn))
12.5.2.5. South Africa Urothelial Cancer Treatment, By Distribution Channel, 2017-2030 (US$ Mn))
12.5.3. Rest of Middle East and Africa
12.5.3.1. Rest of Middle East and Africa Urothelial Cancer Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
12.5.3.2. Rest of Middle East and Africa Urothelial Cancer Treatment, By Type, 2017-2030 (US$ Mn))
12.5.3.3. Rest of Middle East and Africa Urothelial Cancer Treatment, By Treatment, 2017-2030 (US$ Mn))
12.5.3.4. Rest of Middle East and Africa Urothelial Cancer Treatment, By Treatment, 2017-2030 (US$ Mn))
12.5.3.5. Rest of Middle East and Africa Urothelial Cancer Treatment, By Distribution Channel, 2017-2030 (US$ Mn))

13. Company Profiles
13.1. Johnson & Johnson Private Limited
13.1.1. Company Overview
13.1.2. Products/Services Portfolio
13.1.3. Geographical Presence
13.1.4. Financial Summary
13.1.4.1. Market Revenue and Net Profit (2019-2022)
13.1.4.2. Business Segment Revenue Analysis
13.1.4.3. Geographical Revenue Analysis
13.2. Abbott
13.3. AbbVie Inc
13.4. Bausch Health Companies Inc
13.5. Sun Pharmaceutical Industries Ltd
13.6. Aurobindo Pharma
13.7. Lupin
13.8. Hikma Pharmaceuticals PLC
13.9. Amneal Pharmaceuticals LLC
13.10. Pfizer Inc
13.11. Mylan N.V.
13.12. Bristol-Myers Squibb Company
13.13. GSK plc
13.14. Bayer AG
13.15. Dendreon Pharmaceuticals LLC
13.16. Eisai Co., Ltd
13.17. Genentech, Inc
13.18. F. Hoffmann-La Roche Ltd.
13.19. Konninklije Philips N.V.
13.20. Olympus Corporation
13.21. Pacific Edge
13.22. AroCell AB
13.23. Agilent Technologies

List of Figures

FIG. 1 Global Urothelial Cancer Treatment Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Urothelial Cancer Treatment Market Segmentation
FIG. 4 Global Urothelial Cancer Treatment Market, by Type, 2022 (US$ Mn))
FIG. 5 Global Urothelial Cancer Treatment Market, by Treatment, 2022 (US$ Mn))
FIG. 6 Global Urothelial Cancer Treatment Market, by End-Users, 2022 (US$ Mn))
FIG. 7 Global Urothelial Cancer Treatment Market, by Distribution Channel, 2022 (US$ Mn))
FIG. 8 Global Urothelial Cancer Treatment Market, by Geography, 2022 (US$ Mn))
FIG. 9 Attractive Investment Proposition, by Type, 2022
FIG. 10 Attractive Investment Proposition, by Treatment, 2022
FIG. 11 Attractive Investment Proposition, by End-Users, 2022
FIG. 12 Attractive Investment Proposition, by Distribution Channel, 2022
FIG. 13 Attractive Investment Proposition, by Geography, 2022
FIG. 14 Global Market Share Analysis of Key Urothelial Cancer Treatment Market Manufacturers, 2022
FIG. 15 Global Market Positioning of Key Urothelial Cancer Treatment Market Manufacturers, 2022
FIG. 16 Global Urothelial Cancer Treatment Market Value Contribution, By Type, 2022 & 2030 (Value %)
FIG. 17 Global Urothelial Cancer Treatment Market, by Papillary, Value, 2017-2030 (US$ Mn))
FIG. 18 Global Urothelial Cancer Treatment Market, by Flat Carcinoma, Value, 2017-2030 (US$ Mn))
FIG. 19 Global Urothelial Cancer Treatment Market Value Contribution, By Treatment, 2022 & 2030 (Value %)
FIG. 20 Global Urothelial Cancer Treatment Market, by Chemotherapy, Value, 2017-2030 (US$ Mn))
FIG. 21 Global Urothelial Cancer Treatment Market, by Radiotherapy, 2017-2030 (US$ Mn))
FIG. 22 Global Urothelial Cancer Treatment Market, by Immunotherapy, 2017-2030 (US$ Mn))
FIG. 23 Global Urothelial Cancer Treatment Market, by Diagnostic Test, 2017-2030 (US$ Mn))
FIG. 24 Global Urothelial Cancer Treatment Market, by Urine Cytology, 2017-2030 (US$ Mn))
FIG. 25 Global Urothelial Cancer Treatment Market, by Biopsy, 2017-2030 (US$ Mn))
FIG. 26 Global Urothelial Cancer Treatment Market, by Computed tomography scanning, 2017-2030 (US$ Mn))
FIG. 27 Global Urothelial Cancer Treatment Market, by Ultrasound Imaging, 2017-2030 (US$ Mn))
FIG. 28 Global Urothelial Cancer Treatment Market, by Cystoscopy, 2017-2030 (US$ Mn))
FIG. 29 Global Urothelial Cancer Treatment Market, by Others, 2017-2030 (US$ Mn))
FIG. 30 Global Urothelial Cancer Treatment Market Value Contribution, By End-Users, 2022 & 2030 (Value %)
FIG. 31 Global Urothelial Cancer Treatment Market, by Hospitals, Value, 2017-2030 (US$ Mn))
FIG. 32 Global Urothelial Cancer Treatment Market, by Homecare, 2017-2030 (US$ Mn))
FIG. 33 Global Urothelial Cancer Treatment Market, by Speciality Centres, 2017-2030 (US$ Mn))
FIG. 34 Global Urothelial Cancer Treatment Market, by Others, 2017-2030 (US$ Mn))
FIG. 35 Global Urothelial Cancer Treatment Market Value Contribution, By Distribution Channel, 2022 & 2030 (Value %)
FIG. 36 Global Urothelial Cancer Treatment Market, by Hospital Pharmacy, Value, 2017-2030 (US$ Mn))
FIG. 37 Global Urothelial Cancer Treatment Market, by Online Pharmacy, Value, 2017-2030 (US$ Mn))
FIG. 38 Global Urothelial Cancer Treatment Market, by Retail Pharmacy, Value, 2017-2030 (US$ Mn))
FIG. 39 North America Urothelial Cancer Treatment Market, 2017-2030 (US$ Mn))
FIG. 40 U.S. Urothelial Cancer Treatment Market, 2017-2030 (US$ Mn))
FIG. 41 Canada Urothelial Cancer Treatment Market, 2017-2030 (US$ Mn))
FIG. 42 Europe Urothelial Cancer Treatment Market, 2017-2030 (US$ Mn))
FIG. 43 Germany Urothelial Cancer Treatment Market, 2017-2030 (US$ Mn))
FIG. 44 France Urothelial Cancer Treatment Market, 2017-2030 (US$ Mn))
FIG. 45 U.K. Urothelial Cancer Treatment Market, 2017-2030 (US$ Mn))
FIG. 46 Italy Urothelial Cancer Treatment Market, 2017-2030 (US$ Mn))
FIG. 47 Spain Urothelial Cancer Treatment Market, 2017-2030 (US$ Mn))
FIG. 48 Rest of Europe Urothelial Cancer Treatment Market, 2017-2030 (US$ Mn))
FIG. 49 Asia Pacific Urothelial Cancer Treatment Market, 2017-2030 (US$ Mn))
FIG. 50 China Urothelial Cancer Treatment Market, 2017-2030 (US$ Mn))
FIG. 51 Japan Urothelial Cancer Treatment Market, 2017-2030 (US$ Mn))
FIG. 52 India Urothelial Cancer Treatment Market, 2017-2030 (US$ Mn))
FIG. 53 South Korea Urothelial Cancer Treatment Market, 2017-2030 (US$ Mn))
FIG. 54 South-East Asia Urothelial Cancer Treatment Market, 2017-2030 (US$ Mn))
FIG. 55 Rest of Asia Pacific Urothelial Cancer Treatment Market, 2017-2030 (US$ Mn))
FIG. 56 Latin America Urothelial Cancer Treatment Market, 2017-2030 (US$ Mn))
FIG. 57 Brazil Urothelial Cancer Treatment Market, 2017-2030 (US$ Mn))
FIG. 58 Mexico Urothelial Cancer Treatment Market, 2017-2030 (US$ Mn))
FIG. 59 Rest of Latin America Urothelial Cancer Treatment Market, 2017-2030 (US$ Mn))
FIG. 60 Middle East & Africa Urothelial Cancer Treatment Market, 2017-2030 (US$ Mn))
FIG. 61 GCC Countries Urothelial Cancer Treatment Market, 2017-2030 (US$ Mn))
FIG. 62 South Africa Urothelial Cancer Treatment Market, 2017-2030 (US$ Mn))
FIG. 63 Rest of Middle East and Africa Urothelial Cancer Treatment Market, 2017-2030 (US$ Mn))

List of Tables

TABLE 1 Market Snapshot: Global Urothelial Cancer Treatment Market
TABLE 2 Global Urothelial Cancer Treatment Market, by Competitive Benchmarking, 2022
TABLE 3 Global Urothelial Cancer Treatment Market, by Geographical Presence Analysis, 2022
TABLE 4 Global Urothelial Cancer Treatment Market, by Key Strategies Analysis, 2022
TABLE 5 Global Urothelial Cancer Treatment Market, by Type, 2017-2030 (US$ Mn))
TABLE 6 Global Urothelial Cancer Treatment Market, by Treatment, 2017-2030 (US$ Mn))
TABLE 7 Global Urothelial Cancer Treatment Market, by End-Users, 2017-2030 (US$ Mn))
TABLE 8 Global Urothelial Cancer Treatment Market, by Distribution Channel, 2017-2030 (US$ Mn))
TABLE 9 Global Urothelial Cancer Treatment Market, by Geography, 2017-2030 (US$ Mn))
TABLE 10 North America Urothelial Cancer Treatment Market, by Type, 2017-2030 (US$ Mn))
TABLE 11 North America Urothelial Cancer Treatment Market, by Treatment, 2017-2030 (US$ Mn))
TABLE 12 North America Urothelial Cancer Treatment Market, by End-Users, 2017-2030 (US$ Mn))
TABLE 13 North America Urothelial Cancer Treatment Market, by Distribution Channel, 2017-2030 (US$ Mn))
TABLE 14 North America Urothelial Cancer Treatment Market, by Country, 2017-2030 (US$ Mn))
TABLE 15 US Urothelial Cancer Treatment Market, by Type, 2017-2030 (US$ Mn))
TABLE 16 US Urothelial Cancer Treatment Market, by Treatment, 2017-2030 (US$ Mn))
TABLE 17 US Urothelial Cancer Treatment Market, by End-Users, 2017-2030 (US$ Mn))
TABLE 18 Canada Urothelial Cancer Treatment Market, by Type, 2017-2030 (US$ Mn))
TABLE 19 Canada Urothelial Cancer Treatment Market, by Treatment, 2017-2030 (US$ Mn))
TABLE 20 Canada Urothelial Cancer Treatment Market, by End-Users, 2017-2030 (US$ Mn))
TABLE 21 Canada Urothelial Cancer Treatment Market, by End-Users, 2017-2030 (US$ Mn))
TABLE 22 Europe Urothelial Cancer Treatment Market, by Type, 2017-2030 (US$ Mn))
TABLE 23 Europe Urothelial Cancer Treatment Market, by Treatment, 2017-2030 (US$ Mn))
TABLE 24 Europe Urothelial Cancer Treatment Market, by End-Users, 2017-2030 (US$ Mn))
TABLE 25 Europe Urothelial Cancer Treatment Market, by Country, 2017-2030 (US$ Mn))
TABLE 26 Germany Urothelial Cancer Treatment Market, by Type, 2017-2030 (US$ Mn))
TABLE 27 Germany Urothelial Cancer Treatment Market, by Treatment, 2017-2030 (US$ Mn))
TABLE 28 Germany Urothelial Cancer Treatment Market, by End-Users, 2017-2030 (US$ Mn))
TABLE 29 France Urothelial Cancer Treatment Market, by Type, 2017-2030 (US$ Mn))
TABLE 30 France Urothelial Cancer Treatment Market, by Treatment, 2017-2030 (US$ Mn))
TABLE 31 France Urothelial Cancer Treatment Market, by End-Users, 2017-2030 (US$ Mn))
TABLE 32 UK Urothelial Cancer Treatment Market, by Type, 2017-2030 (US$ Mn))
TABLE 33 UK Urothelial Cancer Treatment Market, by Treatment, 2017-2030 (US$ Mn))
TABLE 34 UK Urothelial Cancer Treatment Market, by End-Users, 2017-2030 (US$ Mn))
TABLE 35 Italy Urothelial Cancer Treatment Market, by Type, 2017-2030 (US$ Mn))
TABLE 36 Italy Urothelial Cancer Treatment Market, by Treatment, 2017-2030 (US$ Mn))
TABLE 37 Italy Urothelial Cancer Treatment Market, by End-Users, 2017-2030 (US$ Mn))
TABLE 38 Spain Urothelial Cancer Treatment Market, by Type, 2017-2030 (US$ Mn))
TABLE 39 Spain Urothelial Cancer Treatment Market, by Treatment, 2017-2030 (US$ Mn))
TABLE 40 Spain Urothelial Cancer Treatment Market, by End-Users, 2017-2030 (US$ Mn))
TABLE 41 Rest of Europe Urothelial Cancer Treatment Market, by Type, 2017-2030 (US$ Mn))
TABLE 42 Rest of Europe Urothelial Cancer Treatment Market, by Treatment, 2017-2030 (US$ Mn))
TABLE 43 Rest of Europe Urothelial Cancer Treatment Market, by End-Users, 2017-2030 (US$ Mn))
TABLE 44 Asia Pacific Urothelial Cancer Treatment Market, by Type, 2017-2030 (US$ Mn))
TABLE 45 Asia Pacific Urothelial Cancer Treatment Market, by Treatment, 2017-2030 (US$ Mn))
TABLE 46 Asia Pacific Urothelial Cancer Treatment Market, by End-Users, 2017-2030 (US$ Mn))
TABLE 47 Asia Pacific Urothelial Cancer Treatment Market, by Country, 2017-2030 (US$ Mn))
TABLE 48 China Urothelial Cancer Treatment Market, by Type, 2017-2030 (US$ Mn))
TABLE 49 China Urothelial Cancer Treatment Market, by Treatment, 2017-2030 (US$ Mn))
TABLE 50 China Urothelial Cancer Treatment Market, by End-Users, 2017-2030 (US$ Mn))
TABLE 51 Japan Urothelial Cancer Treatment Market, by Type, 2017-2030 (US$ Mn))
TABLE 52 Japan Urothelial Cancer Treatment Market, by Treatment, 2017-2030 (US$ Mn))
TABLE 53 Japan Urothelial Cancer Treatment Market, by End-Users, 2017-2030 (US$ Mn))
TABLE 54 India Urothelial Cancer Treatment Market, by Type, 2017-2030 (US$ Mn))
TABLE 55 India Urothelial Cancer Treatment Market, by Treatment, 2017-2030 (US$ Mn))
TABLE 56 India Urothelial Cancer Treatment Market, by End-Users, 2017-2030 (US$ Mn))
TABLE 57 South Korea Urothelial Cancer Treatment Market, by Type, 2017-2030 (US$ Mn))
TABLE 58 South Korea Urothelial Cancer Treatment Market, by Treatment, 2017-2030 (US$ Mn))
TABLE 59 South Korea Urothelial Cancer Treatment Market, by End-Users, 2017-2030 (US$ Mn))
TABLE 60 South-East Asia Urothelial Cancer Treatment Market, by Type, 2017-2030 (US$ Mn))
TABLE 61 South-East Asia Urothelial Cancer Treatment Market, by Treatment, 2017-2030 (US$ Mn))
TABLE 62 South-East Asia Urothelial Cancer Treatment Market, by End-Users, 2017-2030 (US$ Mn))
TABLE 63 Rest of Asia Pacific Urothelial Cancer Treatment Market, by Type, 2017-2030 (US$ Mn))
TABLE 64 Rest of Asia Pacific Urothelial Cancer Treatment Market, by Treatment, 2017-2030 (US$ Mn))
TABLE 65 Rest of Asia Pacific Urothelial Cancer Treatment Market, by End-Users, 2017-2030 (US$ Mn))
TABLE 66 Latin America Urothelial Cancer Treatment Market, by Type, 2017-2030 (US$ Mn))
TABLE 67 Latin America Urothelial Cancer Treatment Market, by Treatment, 2017-2030 (US$ Mn))
TABLE 68 Latin America Urothelial Cancer Treatment Market, by End-Users, 2017-2030 (US$ Mn))
TABLE 69 Latin America Urothelial Cancer Treatment Market, by Country, 2017-2030 (US$ Mn))
TABLE 70 Brazil Urothelial Cancer Treatment Market, by Type, 2017-2030 (US$ Mn))
TABLE 71 Brazil Urothelial Cancer Treatment Market, by Treatment, 2017-2030 (US$ Mn))
TABLE 72 Brazil Urothelial Cancer Treatment Market, by End-Users, 2017-2030 (US$ Mn))
TABLE 73 Mexico Urothelial Cancer Treatment Market, by Type, 2017-2030 (US$ Mn))
TABLE 74 Mexico Urothelial Cancer Treatment Market, by Treatment, 2017-2030 (US$ Mn))
TABLE 75 Mexico Urothelial Cancer Treatment Market, by End-Users, 2017-2030 (US$ Mn))
TABLE 76 Rest of Latin America Urothelial Cancer Treatment Market, by Type, 2017-2030 (US$ Mn))
TABLE 77 Rest of Latin America Urothelial Cancer Treatment Market, by Treatment, 2017-2030 (US$ Mn))
TABLE 78 Rest of Latin America Urothelial Cancer Treatment Market, by End-Users, 2017-2030 (US$ Mn))
TABLE 79 Middle East and Africa Urothelial Cancer Treatment Market, by Type, 2017-2030 (US$ Mn))
TABLE 80 Middle East and Africa Urothelial Cancer Treatment Market, by Treatment, 2017-2030 (US$ Mn))
TABLE 81 Middle East and Africa Urothelial Cancer Treatment Market, by End-Users, 2017-2030 (US$ Mn))
TABLE 82 Middle East and Africa Urothelial Cancer Treatment Market, by Country, 2017-2030 (US$ Mn))
TABLE 83 GCC Countries Urothelial Cancer Treatment Market, by Type, 2017-2030 (US$ Mn))
TABLE 84 GCC Countries Urothelial Cancer Treatment Market, by Treatment, 2017-2030 (US$ Mn))
TABLE 85 GCC Countries Urothelial Cancer Treatment Market, by End-Users, 2017-2030 (US$ Mn))
TABLE 86 South Africa Urothelial Cancer Treatment Market, by Type, 2017-2030 (US$ Mn))
TABLE 87 South Africa Urothelial Cancer Treatment Market, by Treatment, 2017-2030 (US$ Mn))
TABLE 88 South Africa Urothelial Cancer Treatment Market, by End-Users, 2017-2030 (US$ Mn))
TABLE 89 Rest of Middle East and Africa Urothelial Cancer Treatment Market, by Type, 2017-2030 (US$ Mn))
TABLE 90 Rest of Middle East and Africa Urothelial Cancer Treatment Market, by Treatment, 2017-2030 (US$ Mn))
TABLE 91 Rest of Middle East and Africa Urothelial Cancer Treatment Market, by End-Users, 2017-2030 (US$ Mn))